Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Liabilities: 2022-2025

Historic Total Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $52.2 million.

  • Stoke Therapeutics' Total Liabilities fell 14.78% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year decrease of 14.78%. This contributed to the annual value of $42.5 million for FY2024, which is 38.16% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Total Liabilities of $52.2 million as of Q3 2025, which was up 5.23% from $49.6 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Total Liabilities high stood at $77.1 million for Q2 2022, and its period low was $42.5 million during Q4 2024.
  • In the last 3 years, Stoke Therapeutics' Total Liabilities had a median value of $64.8 million in 2024 and averaged $60.2 million.
  • Data for Stoke Therapeutics' Total Liabilities shows a maximum YoY crashed of 38.16% (in 2024) over the last 5 years.
  • Stoke Therapeutics' Total Liabilities (Quarterly) stood at $71.2 million in 2022, then decreased by 3.43% to $68.8 million in 2023, then crashed by 38.16% to $42.5 million in 2024, then fell by 14.78% to $52.2 million in 2025.
  • Its last three reported values are $52.2 million in Q3 2025, $49.6 million for Q2 2025, and $56.8 million during Q1 2025.